Patents by Inventor Scott Ronald BRODEUR

Scott Ronald BRODEUR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240059789
    Abstract: Provided herein, in certain aspects, are antibodies that bind to PSMA, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to PSMA and CD3, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.
    Type: Application
    Filed: January 24, 2022
    Publication date: February 22, 2024
    Inventors: Theresa McDevitt, Danlin Dan Qing Yang, Sanjaya Singh, Scott Ronald Brodeur, Jennifer Hertzog
  • Patent number: 11795219
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: October 24, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Walter Carroll Davidson, Pankaj Gupta, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Jr., Haiguang Xiao, Danlin Yang
  • Publication number: 20230265203
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.
    Type: Application
    Filed: October 7, 2022
    Publication date: August 24, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald BRODEUR, Thomas B. FREEMAN, Gerald Henry Nabozny, Meera RAMANUJAM, Paul SCHOLL, Juergen STEFFGEN
  • Publication number: 20220267438
    Abstract: Provided herein are multispecific antibodies that bind to BCMA, GPRC5D and CD3 and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are antibodies that bind to BCMA and antigen-binding fragments thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: August 25, 2022
    Inventors: Ricardo Marcos Attar, Scott Ronald Brodeur, Rajkumar Ganesan, Leopoldo Luistro, Ulrike Philippar, Kodandaram Pillarisetti, Sanjaya Singh, I, Danlin Dan Qing Yang
  • Patent number: 11370818
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 28, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • Publication number: 20220153857
    Abstract: The present invention related to new humanized antanogistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 19, 2022
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias Litzenburger, Sanjaya Singh
  • Patent number: 11242394
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: February 8, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • Publication number: 20220017627
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Application
    Filed: April 16, 2021
    Publication date: January 20, 2022
    Inventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
  • Patent number: 11028169
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: June 8, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Haiguang Xiao, Danlin Yang
  • Patent number: 11008395
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: May 18, 2021
    Assignee: Bristol Myers-Squibb Company
    Inventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
  • Publication number: 20210095020
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: May 11, 2020
    Publication date: April 1, 2021
    Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAFF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, JR., Haiguang XIAO, Danlin YANG
  • Publication number: 20200231687
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Application
    Filed: January 21, 2020
    Publication date: July 23, 2020
    Applicant: Bristol Myers-Squibb Company
    Inventors: Aaron Paul YAMNIUK, Scott Ronald BRODEUR, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Yun WANG, Alfred Robert LANGISH, Guodong CHEN, Stephen Michael CARL, Hong SHEN, Achal Mukundrao PASHINE, Lin Hui SU
  • Publication number: 20190309034
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 10, 2019
    Inventors: Scott Ronald BRODEUR, Keith A. CANADA, Michael DZIEGELEWSKI, Philip Nicholas GORMAN, Pankaj GUPTA, Ashraf KHALIL, John J. MIGLIETTA, Amy Marie NICOLETTI, Qi PAN, David PRESKY, Sanjaya SINGH, Tao WU, Haiguang XIAO
  • Patent number: 10377804
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: August 13, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • Publication number: 20190177420
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.
    Type: Application
    Filed: July 18, 2018
    Publication date: June 13, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Thomas B. Freeman, Gerald Henery Nabozny, Meera Ramanujam, Paul Scholl, Juergen Steffgen
  • Publication number: 20190169301
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: July 10, 2018
    Publication date: June 6, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • Publication number: 20180127474
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: November 6, 2017
    Publication date: May 10, 2018
    Inventors: Scott Ronald BRODEUR, Keith A. CANADA, Michael DZIEGELEWSKI, Philip Nicholas GORMAN, Pankaj GUPTA, Ashraf KHALIL, John J. MIGLIETTA, Amy Marie NICOLETTI, Qi PAN, David PRESKY, Sanjaya SINGH, Tao WU, Haiguang XIAO
  • Patent number: 9840543
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: December 12, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith Canada, Mlchael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John James Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • Publication number: 20170334995
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: May 18, 2017
    Publication date: November 23, 2017
    Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAFF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, Jr., Haiguang XIAO, Danlin YANG
  • Publication number: 20170058039
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 2, 2017
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias LITZENBURGER, Sanjaya SINGH